Topic 378: Symptomatic Toxicity Mobile Monitor (SympTMM)

这项NIH第一阶段SBIR提案的目标是开发和验证一种新的方法来监测 癌症患者的症状毒性和健康相关的生活质量， 在治疗过程中正在接受和已经接受放射治疗。的 该提案是围绕移动的应用程序开发的专业知识（Vivonics Inc.）和 放射肿瘤学（马萨诸塞州医学院的TJ Fitzgerald博士）。一期 将允许这个唯一合格的团队开发、测试和验证拟议的移动的 我们称之为症状毒性移动的监测器（SymptomToxicity Monitor，SymptomTM）。 癌症治疗的质量和可用性的改善导致了显著的 癌症患者存活人数的增加，往往是以前无法想象的 年数。2012年，64%的患者存活超过5年，40%超过10年， 15%在诊断后大于20（De摩尔，Mariotto等人，2013）。需要注意的是， 虽然幸存者的寿命更长，但每年新增癌症患者的数量稳步增长。 增加。这一趋势预计将在未来十年继续下去，我们有限的税收 了解对目前使用的各种治疗方法的长期影响

The goal of this NIH Phase I SBIR proposal is to develop and validate a new method to monitor the symptomatic toxicities and health-related quality of life of cancer patients who are undergoing and have undergone radiation therapy during the course of their treatment. The proposal is built around expertise in mobile application development (Vivonics Inc.) and radiation oncology (Dr. TJ Fitzgerald of the University of Massachusetts Medical School). Phase I will allow this uniquely qualified team to develop, test, and validate the proposed mobile application that we call Symptomatic Toxicity Mobile Monitor (SympTMM). Improvements to both the quality and availability of cancer treatment has led to a marked increase in the number of patients surviving cancer, often times for a previously unimaginable number of years. In 2012, 64% of patients survived greater than 5 years, 40% greater than 10, and 15% greater than 20 after diagnosis (De Moor, Mariotto et al. 2013). The caveat is that while survivors are living longer, the volume of new cancer patients each year is steadily increasing. This trend is expected to continue over the coming decade, taxing our limited understanding of the longer-term impacts on the various treatments used today